Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy

Patrícia M.R. Pereira¹, Sai Kiran Sharma¹, Lukas M. Carter¹, Kimberly J. Edwards¹, Jacob Pourat¹, Ashwin Ragupathi³, Yelena Y. Janjigian², Jeremy C. Durack¹,³ & Jason S. Lewis¹,³,⁴,⁵,⁶

Human epidermal growth factor receptor 2 (HER2) gene amplification and/or protein overexpression in tumors is a prerequisite for initiation of trastuzumab therapy. Although HER2 is a cell membrane receptor, differential rates of endocytosis and recycling engender a dynamic surface pool of HER2. Since trastuzumab must bind to the extracellular domain of HER2, a depressed HER2 surface pool hinders binding. Using in vivo biological models and cultures of fresh human tumors, we find that the caveolin-1 (CAV1) protein is involved in HER2 cell membrane dynamics within the context of receptor endocytosis. The translational significance of this finding is highlighted by our observation that temporal CAV1 depletion with lovastatin increases HER2 half-life and availability at the cell membrane resulting in improved trastuzumab binding and therapy against HER2-positive tumors. These data show the important role that CAV1 plays in the effectiveness of trastuzumab to target HER2-positive tumors.
Unrestrained activation of human epidermal growth factor receptor 2 (HER2) contributes to aberrant tumor growth; and HER2 gene amplification, messenger RNA or protein overexpression, has been observed in patients with breast or ovarian cancer. HER2 overexpression has also been reported in patients with gastric cancer, bladder carcinomas, gallbladder, and extrahepatic cholangiocarcinomas. HER2 has no known ligand, but remains the most preferred dimerization partner to potentiate downstream oncogenic signaling by members of the HER family. Prior to the development of targeted anti-HER2 therapy, patients with HER2-positive tumors demonstrated reduced disease-free survival compared to patients whose tumors expressed low levels of HER2. These findings established HER2 as a therapeutic target and a tumor biomarker. Over the past two decades, clinical evidence has unequivocally demonstrated that the inhibition of this oncogene improves treatment outcomes, and has led to the emergence of several effective anti-HER2 therapies.

Among these agents, anti-HER2 therapeutic antibodies (e.g., trastuzumab and pertuzumab), antibody-drug conjugates (ADCs, e.g., trastuzumab emtansine; TDM1), and trastuzumab imaging agents (when radio- or fluorescently-labeled) have changed the prognosis of both breast and gastric cancer patients. However, heterogeneity in HER2 expression or equivocal HER2 status warrants attention in trastuzumab-based imaging and therapeutic strategies. A lack of correlation between histologic HER2 positivity and tumor uptake of, e.g., zirconium-89 (89Zr)-labeled trastuzumab has been observed in patients with breast cancer. These results suggest that determination of overall amplification and/or overexpression of HER2 alone are insufficient to predict response to treatment with trastuzumab.

Clinically, the anti-tumor activity of trastuzumab is attributed to more than a single mechanism of action. Direct action of the antibody is premised on receptor downregulation and subsequent alterations to intracellular signaling including attenuation of downstream pro-tumorigenic cell signaling, inhibition of HER2 shedding, and inhibition of tumor angiogenesis. On the other hand, indirect action due to activation of an immune response via antibody dependent cell-mediated cytotoxicity (ADCC) has also been proposed as a mechanism of action for this drug. Trastuzumab binding to cancer cells is highly dependent on the availability of HER2 at the cell membrane. The current status of patient selection for trastuzumab therapy is based on HER2 positivity using DNA- and protein-based assays. However, these assays could overestimate HER2 positivity, as some of the stained antigen may be intracellular and, therefore, unavailable to engage trastuzumab at the tumor cell surface. This would translate as minimal benefit to such patients from trastuzumab-based therapy since the antibody can only target HER2 available at the cell membrane.

Notably, cell-surface receptors involved in tumor development are characterized by abnormal trafficking from the cell membrane to intracellular compartments. Distinct from HER2, endocytosis of the other members of the HER family occurs after ligand binding. Although HER2 has no known ligand, the open conformation of the extracellular domain contributes to the dynamics of the HER2 surface pool. The localization of HER2 at the membrane is a heterogeneous and dynamic process governed by differential rates of endocytosis and recycling. In addition to cell membrane expression, HER2 localizes in the cytoplasm and nucleus.

Several studies have demonstrated that at the cell membrane, HER2 is localized in caveolea domains. Caveolea are caveolin-1 (CAV1) enriched subdomains of the plasma membrane, which are deregulated in cancer cells and contain a high content of cholesterol and sphingolipids. Others have demonstrated that HER2 co-localizes with the lipid-raft marker GM1 and interacts with the lipid-raft associated oncoprotein mucin-1. After binding to the extracellular domain of HER2, the tumor suppressor opioid binding protein/cell adhesion molecule like (OPCML) induces HER2 degradation through the caveolea-associated endosomal pathway. Importantly, the depletion of membrane cholesterol results in HER2 confinement at the cell membrane.

Intrinsic defects in the endocytic machinery responsible for HER2 downregulation correlate with unresponsiveness to trastuzumab therapy. It is suggested that caveolea-mediated endocytosis is involved in resistance to treatment with TDM1 and trastuzumab. We hypothesize that modulation of the caveolea membrane domains could promote stability of HER2 at the cell membrane and improve binding of trastuzumab to target cells. In this study, we demonstrate how CAV1 can influence HER2 expression and stability at the cell membrane.

Results

HER2 interacts with CAV1. To address cell-surface HER2 stability in CAV1-positive vs. CAV1 negative cells, we first explored protein–protein associations between HER2 and CAV1 in a panel of cancer cell lines (Fig. 1a and Supplementary Fig. 1a, b). Mining the Cancer Cell Line Encyclopedia database, a panel of 14 cell lines supported the inverse correlation between HER2 and CAV1 protein expression (−0.38, P = 0.03, Spearman’s correlation). Western blot analysis of a panel of 14 cell lines supported the inverse correlation between HER2 and CAV1 protein expression (−0.58, P = 0.03, Spearman’s correlation). The network generated for HER2 and CAV1 proteins using the STRING database revealed that CAV1 has a negative molecular action on HER2. Altogether, these findings support a seesaw effect between CAV1 and HER2 proteins.

CAV1 contributes to cell membrane HER2 density. Given that CAV1 associates with HER2 and that CAV1 expression in malignancies may be clinically significant for cancer diagnosis, we sought to determine if CAV1 expression is correlated with HER2 density at the cell membrane. We observed that HER2 does not exhibit predominant membrane localization in all cell clusters of NCI87 (HER2-positive gastric cancer cell line) xenografts (Fig. 1b). These observations are consistent with recent reports of HER2-positive gastric tumors having different HER2 densities at the cell membrane. In cancer cells where CAV1 is absent, HER2 is exclusively present at the cell membrane (Fig. 1c highlighted by the dashed white circles 1 and 3). On the other hand, cancer cells expressing CAV1 exhibit reduced HER2 staining at the cell membrane (Fig. 1c highlighted by the dashed white circles 2 and 4). Consistent with these findings, immunofluorescence staining of HER2-positive tumor samples obtained from gastric cancer patients revealed that cells with high expression of CAV1 have low membrane staining of HER2. In HER2-positive tumor samples containing low expression levels of CAV1, HER2 exhibits predominant membrane staining. Altogether, the immunofluorescence analyses of...
Fig. 1 Seesaw effect between CAV1 and HER2 proteins. **a** Association between CAV1 and HER2 in gastric (NCIN87, KATOIII), bladder (HT1197, UMUC14, UMUC3), breast (MDAMB231, MCF-7, BT474, SKBR3), pancreatic (BxPc3, MiaPaCa, Suit2) and prostate (LnCap, Pc3) cancer cells. The level of CAV1 (y-axis) and HER2 (x-axis) are expressed as the ratio of protein/β-actin control, as determined by western blot analysis (upper panel). The non-parametric one-tailed Spearman test was used to determine the correlation coefficients. $R_{HER2/CAV1}$, ratio of HER2-to-CAV1 protein levels as determined by western blot analysis from total extracts (lower panel).

**b** Confocal images of immunofluorescence staining of HER2 in s.c. NCIN87 gastric tumors from athymic nude mice, showing that HER2 does not exhibit a predominant membrane staining. Scale bars: 100 μm and 50 μm (inset).

**c** Confocal images of immunofluorescence staining of HER2 and CAV1 in s.c. NCIN87 gastric tumors from athymic nude mice. HER2 presence at the cell membrane in cells where CAV1 is absent (cell clusters 1 and 3) and HER2 almost absent at the cell membrane in cells where CAV1 is present (cell clusters 2 and 4). Scale bars: 50 μm.

**d** Confocal images and quantification (mean ± S.E.M, n = 3) of immunofluorescence staining of HER2 and CAV1 in human HER2-positive gastric tumors containing high (Patient 1) and low (Patient 2) expression of CAV1. HER2 predominant presence at the cell membrane in CAV1-negative tumors (Patient 2). Scale bars: 50 μm.

**f** Western blot analysis of the distribution of HER2 and CAV1 in caveolae fractions isolated from NCIN87 cells. Western blot of HER2 and CAV1 in the total lysates of NCIN87 cells after blocking protein synthesis with 80 μg mL$^{-1}$ CHX for 0, 12, 24, 30, 48, 60, 72, and 96 h. CHX cyclohexamide. HER2 and CAV1 have similar half-lives. Half-lives calculated after western blot analysis of Fig. 1f. Density of western blot bands was quantified by scanning densitometry with ImageJ software. Half-lives were calculated as the time required for protein decrease to 50% of its initial level (mean ± S.E.M, n = 4)
preclinical and clinical samples indicate that CAV1 expression plays a role in HER2 antigen density at the cell membrane.

Additional subcellular fractionation experiments confirmed that HER2 is present, with CAV1, in the same lipid-rich fractions (Fig. 1e). HER2 and CAV1 half-lives were estimated in cells treated with an inhibitor of protein biosynthesis, cycloheximide, CHX (Fig. 1f, g and Supplementary Fig. 2). The actin-normalized HER2 or CAV1 protein expression levels (relative to t = 0) were plotted over time, and protein half-life was estimated from a monophasic exponential fit using GraphPad Prism (Fig. 1g). The estimated half-life of HER2 was similar to CAV1 in NCIN87 gastric, BT474 and SKBR3 breast cancer cell lines. Collectively, these results support the association between CAV1 and HER2.

Depletion of CAV1 improves trastuzumab binding. The inverse correlation between CAV1 and HER2 expression led us to investigate if depletion of CAV1 would result in improved HER2 stability at the cell membrane. To this end, we first used a pool of three target-specific 20–25 nucleotides (nt) small-interfering RNA (siRNA) to knockdown CAV1 protein (Supplementary Fig. 3a). Cell-surface biotinylation experiments were performed to analyze HER2 expression and localization in the plasma membrane. siRNA-mediated knockdown of CAV1 slightly increased (1.4 ± 0.2, mean ± S.E.M, n = 3) HER2 at the cell membrane for NCIN87 cells (Fig. 2a) and UMUC14 cells (Supplementary Fig. 3b), without alteration of total HER2 protein levels. In contrast, when we used clustered regularly interspaced short palindromic repeats (CRISPR) activation plasmid to increase CAV1, we found that forced CAV1 overexpression promotes loss of HER2 at the cell membrane (Fig. 2b and Supplementary Fig. 3c). While CAV1 depletion resulted in a slight increase in cell-surface HER2, a more pronounced effect of knocking down CAV1 was demonstrated by the extended half-life.
(P < 0.05, Student’s t-test) of HER2 at the cell membrane (Fig. 2c, d and Supplementary Fig. 3d, e) in NCIN87, UMUC14, and BT474 cancer cells. Knockdown of CAV1 in HER2-positive SKBR3 breast cancer cell line, did not impact the HER2 cell–surface half-life (Supplementary Fig. 3f) plausibly due to the low levels of caveolae in this cell line31 (Supplementary Fig. 1a). In direct comparison, the membrane-bound HER2 half-life was 2.2-, 1.5-, and 2.0-fold higher in CAV1-depleted NCIN87, UMUC14 and BT474 cells, respectively.

Following trastuzumab binding, HER2 is internalized from the plasma membrane and accumulates in sorting endosomes. Thereafter, it can either recycle back to the cell surface or be degraded in the lysosomes39. We sought to investigate if decreased trastuzumab-mediated HER2 internalization could be achieved by a temporal and acute depletion of CAV1. To this end, trastuzumab was allowed to bind HER2 on NCIN87 cells treated with a scrambled (Scr) siRNA (control) vs. cells treated with a CAV1-depleting siRNA. The cells were allowed to undergo trastuzumab-mediated endocytosis for at least 90 min after surface biotinylation, and the internalized fraction of HER2 was evaluated via immunoblotting (Fig. 2e and Supplementary Fig. 4a). Incubation with trastuzumab depresses the surface pool of HER2 (Fig. 2f) as the receptor is internalized in a time-dependent manner. Notably, compared to scr cells, a marked decrease in HER2 endocytosis was observed in CAV1-depleted NCIN87 cells. Cellular fractionation of CAV1-depleted cancer cells treated with 89Zr-labeled trastuzumab revealed a significant increase (P < 0.001, Student’s t-test) in membrane-associated radioactivity (Fig. 2g and Supplementary Fig. 4b). Increased membrane-associated 89Zr-labeled trastuzumab was also observed upon depletion of cholesterol using methyl-β-cyclodextrin (MβCD) and filipin (Fig. 2g and Supplementary Fig. 4b). Next, the binding profile of 89Zr-labeled trastuzumab in competitive radioligand saturation-binding assays confirmed that CAV1 knockdown increased HER2 density on the cell membrane (R_{max}) (Fig. 2h and Supplementary Fig. 4c). Altogether, these data indicate that CAV1 depletion stabilizes HER2 at the cell membrane and improves the tumor avidity for trastuzumab on HER2-positive cancer cells.

CAV1 can be downregulated in vivo by lovastatin. Premised on our in vitro findings, we expected that HER2-positive tumors containing high levels of CAV1 would have a low surface pool of HER2. This in turn would impact the ability of trastuzumab to target and treat HER2-positive cancer cells. Therefore, we sought to investigate whether CAV1 depletion might result in an increased uptake of trastuzumab in tumor xenografts and human tumor samples. However, to date, there are no commercially available CAV1-specific modulators. Nevertheless, protein levels of CAV1 can be reduced by disruption of cholesterol-rich membrane domains using cholesterol-lowering drugs30,39. Lovastatin is one such commercially available drug that is prescribed worldwide to normalize lipid content in individuals having high blood cholesterol levels. In our study, lovastatin was used as a pharmacological modulator of CAV1. Previous studies have reported that 25 μM of lovastatin reduces the protein expression of CAV1 in vitro40. In our studies, the active form of lovastatin effectively depleted CAV1 expression in NCIN87 cells without altering phosphorylated HER2 levels (Fig. 2i). Thus, we further explored the potential role of lovastatin as a CAV1 modulator in the context of trastuzumab binding to NCIN87 cells. A potent role for the active form of lovastatin in increasing trastuzumab binding to cancer cells was also demonstrated via competitive radioligand saturation-binding assays (Fig. 2h and Supplementary Fig. 4c). These results seem to indicate that the increased binding of trastuzumab to HER2-positive cancer cells after treatment with lovastatin is a result of an overall increase in the binding between trastuzumab and HER2. Using fluorescence microscopy, trastuzumab was found not only on the surface of cancer cells, but also in intracellular vesicles (Fig. 2) and Supplementary Movie 1). However, in the presence of lovastatin, trastuzumab exhibited predominant membrane staining (Fig. 2) and Supplementary Movie 2). Lovastatin’s inhibition of the enzyme 3-hydroxyl-3-methylglutarylcoenzyme A (HMG-CoA) reductase (HMGR) is known to result in the decrease of mevalonate and its downstream products (e.g., cholesterol). In the presence of lovastatin, cells exhibited an increase in membrane-associated 89Zr-labeled trastuzumab, an effect that is rescued by the addition of mevalonate to the cell culture (Fig. 3a and Supplementary Fig. 4d). Additional studies demonstrated that an increment in membrane cholesterol content has the opposite effect (Fig. 3a and Supplementary Fig. 4d). In sum, our findings suggest that lovastatin may be able to pharmacologically modulate HER2 endocytosis through a CAV1-mediated mechanism.

Further to these findings, we explored the efficiency of lovastatin to deplete CAV1 in NCIN87 xenografts. Two doses of lovastatin (8.3 mg kg⁻¹ of mice), administered within 12 h of each other, was established as the most efficient treatment regimen that yielded a significant reduction in the total levels of CAV1 protein (Fig. 3b). Since the extracellular domain of HER2 is known to shed in vivo, we evaluated the impact of lovastatin treatment on this phenomenon. Specifically, treatment with lovastatin reduced HER2 shedding by approximately 50% in vitro using NCIN87 cells vs. 70% in NCIN87 xenografts (Fig. 3c). HER2 localization at the plasma membrane was increased in NCIN87 xenografts treated with lovastatin vs. saline-treated control mice (Fig. 3d–f and Supplementary Fig. 5). No further reduction of CAV1 concomitant with an increase in cell surface HER2 in tumors could be observed when mice were treated with lovastatin for longer than 60 h. Collectively, these results demonstrate that CAV1 can be temporally modulated in vitro and in vivo via pharmacological treatment with a statin.
as an orally administered formulation, further studies were performed using oral administration of lovastatin 12 h prior and at the same time of trastuzumab injection. The 12 h window was chosen since immunoblotting and immunofluorescence data demonstrated that CAV1 was significantly reduced in the tumor with a concomitant increase in HER2 at the cell membrane at this time point (Fig. 3). Control mice were orally administered saline instead of lovastatin. Longitudinal PET imaging of these mice revealed tumors that were clearly delineated as early as 4 h post-injection of trastuzumab and yielded high contrast images at 48 h post-injection of the radiotracer (Fig. 4a). Ex vivo biodistribution studies further validated our findings from PET imaging (Fig. 4b). The saline-treated cohort yielded a radiopharmacologic profile typical of 89Zr-labeled trastuzumab, which shows a gradual accretion into the HER2-positive tumors (2.6 ± 1.3% ID g⁻¹ at 4 h to 17.5 ± 6.9% ID g⁻¹ at 48 h). On the other hand, xenograft mice treated with lovastatin yielded a remarkably high tumor uptake of 9.1 ± 4.6% ID g⁻¹ as early as 4 h post-injection of 89Zr-labeled trastuzumab, which rose to 27.1 ± 7.6 at 48 h. High tumor-to-background ratios were achieved in mice pretreated...
with lovastatin (Supplementary Fig. 7a, b). The tumor uptake of a radiolabeled isotype control IgG was significantly low and comparable in both CT mice as well as those treated with lovastatin (Supplementary Fig. 7c). These results indicate that a temporal depletion of CAV1 by lovastatin increases cell surface HER2, which in turn enhances the avidity of HER2-positive tumors for trastuzumab and accelerates tumor uptake of 89Zr-trastuzumab.

In addition to the conventional in vitro and in vivo studies, our findings were validated in organotypic cultures of fresh human bladder tumors. Tissues of HER2-positive bladder tumors were sliced immediately upon harvest during surgery, and grown in culture-plate inserts. Viability assays of tumor slices revealed no significant loss of viable cells (Supplementary Fig. 8a, b) during 96 h of ex vivo culture (P < 0.05, Student’s t-test). After ex vivo treatment with the active form of lovastatin, the tumor slices showed an increased uptake of 89Zr-trastuzumab (P < 0.05, Student’s t-test; Fig. 4c). In non-tumor bladder tissue, lovastatin treatment did not significantly increase tissue accumulation of 89Zr-trastuzumab. Western blot analysis revealed a decrease in CAV1 protein expression after lovastatin treatment (Supplementary Fig. 8c), lending further support to our central hypothesis that temporal CAV1 depletion increases trastuzumab binding to HER2-positive tumors. Additionally, through this experiment, we were able to demonstrate the utility of organotypic cultures as a potential ex vivo biological model to study the accumulation of target-specific radiolabeled antibodies in clinically relevant tumor tissues.

**CAV1 depletion enhances trastuzumab therapeutic efficacy.** To assess the efficacy of trastuzumab treatment when combined with CAV1 depletion in vivo, we conducted therapy studies in mice bearing NCIN87 gastric and BT474 breast, and gastric cancer PDXs. The gastric PDX model was established by implantation of HER2-positive and CAV1-positive gastric tumor tissue from Patient 1 (Fig. 1d) in immunodeficient NOD-SCID gamma (NSG) mice. Mice were treated weekly with 5 mg kg\(^{-1}\) of lovastatin for 5 weeks. Two doses of lovastatin (4.15 mg kg\(^{-1}\)) were orally administered 12 h prior and at the same time as the intraperitoneal injection of trastuzumab. No difference was seen between the vehicle and lovastatin groups (Fig. 4d). Mice treated with either trastuzumab alone or trastuzumab combined with lovastatin showed tumor growth inhibition. However, the therapeutic efficacy of trastuzumab combined with lovastatin was significantly improved compared with trastuzumab alone. Taken together, our findings suggest that CAV1 depletion enhances trastuzumab uptake and therapeutic efficacy by increasing the expression of the target receptor, HER2, on tumor cells.
together, these results show that the in vivo therapeutic efficacy of trastuzumab is remarkably improved when the tumors are temporally depleted of CAV1—despite the latter being a transient effect.

One of the mechanisms of action of trastuzumab is by inducing tumor cell death via ADCC. A prerequisite to this phenomenon is the binding of trastuzumab to HER2 on tumor cells. Thus, trastuzumab-mediated ADCC is an effect that is closely related with HER2 density at cell membrane42. We attempted to study in vitro ADCC upon CAV1 depletion in NCI-N87 gastric and BT474 breast cancer cells (T) using peripheral blood mononuclear cells (PBMCs) from healthy donors and engineered Jurkat cells as effector cells (E) that stably express the FcγRIIIα receptor. CAV1-depleted NCI-N87 and BT474 cancer cells showed increased in vitro ADCC when PBMCs were used as effector cells (E/T ratio = 50:1, Fig. 4e). When engineered Jurkat cells were used as effector cells, CAV1 depletion in NCI-N87 and BT474 cancer cells resulted in a decrease in IC50 values (E/T = 15:1, Fig. 4e and Supplementary Fig. 9).

Discussion
Endocytosis of receptors of the EGFR family is a complex biological process that remains to be completely understood. Nevertheless, intrinsic defects in this process have been demonstrated to influence therapeutic outcomes in EGFR-directed therapies25,34,43. Treatment of HER2-positive tumors with trastuzumab is premised on the presence of HER2 on the membrane of tumor cells. Therefore, the stability and availability of cell surface HER2 is an important predictor of trastuzumab efficacy. In the work at hand, we show that CAV1 knockdown reduces HER2 internalization and extends the half-life of HER2 at the cell membrane while concomitantly decreasing HER2 shedding without altering HER2 activity. Furthermore, accumulation of cell surface HER2 in response to pharmacological depletion of CAV1 was observed using preclinical xenograft models and organotypic cultures derived from freshly harvested human tumors. The discovery that CAV1 modulates cellular distribution of HER2 may have direct therapeutic implications for antibody-mediated targeting of HER2 and the use of such antibodies for molecular imaging and therapy of HER2-positive tumors.

CAV1 has been shown to regulate downstream signaling by members of the HER family19,20,23,34 and interferes with the uptake/activity of a wide variety of antibodies or ADCs targeting the HER family29,36,44–46. Here, we show that the inverse correlation between cellular expression of CAV1 and HER2 directly affects the stability and localization of HER2 on the cell membrane. Our findings are supported by other reports that show CAV1 interaction with signaling molecules such as epidermal growth factor (EGF)45. Others have also previously demonstrated that although EGF is a ligand for its cognate receptor—EGFR, EGF treatment promotes the formation of heterodimers between EGFR and HER2, which activates HER247. Further studies are necessary to evaluate the consequences of lovastatin treatment on the dimerization status of HER2.

Indeed, HER2 localization at the cell membrane is the product of a highly dynamic process23 involving endocytosis, cytoplasmic recycling, and de novo synthesis. Furthermore, the membrane localization of HER2 is heterogeneous within tumors (Fig. 1b, c). Previous studies have reported that even at the single-cell level, individual HER2 molecules do not function in a uniform manner48, and that this non-uniform behavior contributes to receptor heterogeneity. Equipped with this information, we analyzed patient tumor samples using immunofluorescence to understand how CAV1 expression patterns may relate to the cellular localization of HER2. Not surprisingly, a higher cell surface localization of HER2 was found in human tumor tissues containing low levels of CAV1 (Fig. 1d). Conversely, tumors containing high levels of CAV1 had a low amount of HER2 localized at the cell membrane (Fig. 1d). Of course, a prerequisite for trastuzumab binding to HER2 is the latter’s presence on the surface of a cancer cell and not within intracellular compartments. Taken together, these observations led us to hypothesize that CAV1 expression can be leveraged as a complementary biomarker to identify patients who would or would not benefit from HER2-targeted therapy with trastuzumab. Our findings in this study support previous reports that are suggestive of CAV1’s role in the therapeutic response to HER2-targeted therapies35,36,44,49,50. Our studies clearly establish that downregulation of CAV1 increases HER2 availability at the cell surface.

Receptor-mediated endocytosis of ADCs such as TDM1 is central to the mechanism of action of this class of drugs. Indeed, the internalization of ADCs precedes the release of the cytotoxic drug within the lysosomal compartment of the cell, leading to cell death and manifestation of tumor regression. Others have demonstrated that the addition of nuclear localization sequence (NLS) peptides to trastuzumab labeled with an au"e" electron-emitter increases the internalization and nuclear localization of the antibody to decrease clonogenic survival of tumor cells51 as well as to overcome insulin-like growth factor(IGF)-receptor-induced trastuzumab resistance in breast cancer cells52. In light of these reports, it would seem counter-productive to prevent HER2 internalization via pharmacological depletion of CAV1, as this might reduce the therapeutic benefit of HER2-directed ADCs. However, our data suggests that the temporal modulation of CAV1 extends the half-life of HER2 at the tumor cell surface to enhance the tumor’s avidity for trastuzumab. The presence of such a target-rich sink could ultimately drive the in vivo pharmacokinetics of trastuzumab in favor of target-mediated drug disposition—leading to a significantly enhanced accumulation of trastuzumab in the tumor at early time points. Finally, being a transient and temporally controlled phenomenon that occurs under the influence of a pharmacological modulator of CAV1, normalization of the cellular distribution of HER2 including receptor-mediated internalization of the antibody bound to it would occur once the transient in vivo effect of the CAV1 modulator has worn out. Our finding that CAV1 depletion improves trastuzumab therapy, suggests that temporal modulation of CAV1 by a statin could be a strategy that can be applied in the clinic to improve trastuzumab binding/therapy for the treatment of HER2-positive tumors (Fig. 4). Admittedly, despite the successful in vitro demonstration of an effective trastuzumab-mediated ADC potency mediated by treatment with lovastatin, we realize that ADCC may not be a predominant mechanism of action contributing to the therapeutic efficacy of trastuzumab and/or combination of trastuzumab with lovastatin in our preclinical in vivo studies, since these experiments were performed using immunodeficient mice.

Statins, methyl-β-cyclodextrin, filipin, nystatin, and cholesterol oxidase are well known pharmacological inhibitors of caveolae/lipid-raft mediated endocytosis. Additionally, selective inhibition of lipid-raft/caveola-mediated endocytosis can be achieved via acute depletion of the plasma membrane cholesterol. Depletion of cholesterol with methyl-β-cyclodextrin has been shown to release EGFR from lipid rafts, which increases the binding of iodine-125 (125I)-labeled EGF53. Others have shown that cholesterol contributes to the cellular dynamics of HER2 and EGFR35. Here, we demonstrate that the bioavailability of HER2 at the cell membrane can be modulated via temporal depletion of cholesterol by lovastatin in ways that could serve to enhance trastuzumab binding and therapy against HER2-positive tumors (Figs. 3 and 4). For example, a reduction in the in vivo shedding of HER2
from proteolytic cleavage by sheddases might contribute to our observations of increased trastuzumab accumulation in HER2-positive tumors (Fig. 3c). HER2 shedding generates soluble truncated HER2 molecules in the serum54. 89Zr-labeled trastuzumab has been proposed to bind the shed extracellular domain of HER255, which contains the binding site for trastuzumab. Notably, cholesterol depletion from cell membranes alters the function of enzymes with sheddase activity56. Taken together with our findings, it may be plausible that increased trastuzumab accumulation in membrane-bound fractions may also be a result of decreased shedding of HER2.

Despite being an effective modulator of CAV1 in our experiments, lovastatin is a lactone pro-drug that is plagued by poor oral bioavailability (<5%) owing to its lipophilic nature57. After oral administration, lovastatin undergoes extensive first-pass metabolism and is hydrolyzed to the active beta-hydroxyacid form, which competitively inhibits HMGCGR. HMGCGR is the rate-limiting enzyme of cholesterol synthesis and is deregulated or elevated in several tumor types58. The bioavailability of lovastatin in systemic circulation is low and variable. It has a plasma half-life of 1.1–1.7 h, and takes approximately 2 to 4 h to reach maximum concentration in circulation. Only after metabolism and re-entry into systemic circulation, does lovastatin stand a chance to reach the tumor. The maximum human dose of lovastatin is 80 mg per day (1.33 mg kg−1 per day for a 60 kg adult). The doses of lovastatin used in our imaging and therapy studies—8.33 and 4.15 mg kg−1—correspond to human equivalent doses of 0.68 and 0.34 mg kg−1, which are significantly lower than the maximum recommended daily dose in humans. Previous preclinical studies have demonstrated the therapeutic potential of lovastatin per se using doses between 5 to 10 mg kg−159.

In our study, lovastatin was able to decrease CAV1 protein levels and increase cell membrane HER2 after 12 h of oral administration (Fig. 3). The low bioavailability of lovastatin and its short half-life suggests that a limited fraction of lovastatin would have reached the tumor after oral administration. It is expected that a more specific and efficient delivery of lovastatin to the tumors might further improve HER2 localization at the cell surface. Indeed, our findings support the surge in the interest for the use of statins for cancer treatment and the potential benefits thereof41,58,60.

Since many cancer patients use statins, our data provides a rationale to pursue a clinical study combining lovastatin with trastuzumab to evaluate if this combination might positively affect the therapeutic outcomes or imaging strategies using trastuzumab in HER2-positive patients.

From the perspective of immunoPET, our study presents a major advance in the field of molecular imaging. Traditionally, the sluggish in vivo pharmacokinetics of full-length antibodies has necessitated their radiolabeling with long-lived positron-emitting radionuclides such as zirconium-89 (t1/2 = 78.2 h) to yield high contrast images between 72–120 h post-injection of the radioimmunoconjugate tracer. However, this manifests as a logistical inconvenience requiring patients to return to the clinic for a PET scan 4–5 days after they have been injected with the tracer6. However, we were able to obtain high contrast PET images as early as 4 h post-injection of 89Zr-radiolabeled trastuzumab in HER2-positive tumors wherein CAV1 was pharmacologically modulated by using lovastatin (Fig. 4). Such an accelerated accumulation of 89Zr-labeled trastuzumab is of tremendous clinical relevance from the standpoint of being able to overcome the current pharmacokinetic limitation of full-length antibodies to achieve same- to next-day immunoPET imaging in patients. This aspect further supports the rationale for combining a cholesterol-lowering drug such as a statin with trastuzumab to facilitate a relatively rapid turnaround time for the diagnosis of HER2-positive tumors via molecular imaging with full-length antibodies.

In conclusion, our study establishes the inverse relationship between CAV1 expression and HER2 localization at the cell membrane, and how this relationship can be pharmacologically modulated to augment HER2-targeted therapy of various cancers. Our findings suggest that CAV1 can be a promising biomarker to select patients for trastuzumab therapy. Finally, our preclinical data demonstrate the potential benefit of using statins to improve the therapeutic efficacy of trastuzumab and advance HER2-targeted molecular imaging in the clinic.

**Methods**

**Cell lines and patient samples.** Gastric human cancer cell lines NCIN87 and KATOII, breast cancer cell lines MDA-MB-231, SK-BR-3, MCF-7, and BT474 were purchased from American Type Culture Collection (ATCC). The human bladder cancer cell line, UMUC14, was obtained from Sigma-Aldrich. All cell lines were mycoplasma free and maintained at 37 °C in a humidified atmosphere at 5% CO2. Cell lines utilized in this work were purchased in 2014–2016, and were used within passage number of 15. All the cell lines were authenticated at Memorial Sloan-Kettering Cancer Center (MSKCC) integrated genomics operation core using short tandem repeat analysis. Deidentified patient gastric and bladder cancer samples were obtained from Memorial Hospital following IRB approval. PBMCs, obtained from the Immune Monitoring Facility at MSKCC, were separated from the blood of normal volunteers using lymphocyte separation medium (MP Biomedicals). Patients provided informal consent.

**Cell culture.** NCIN87 cells were grown in Roswell Park Memorial Institute (RPMI)-1640 growth medium supplemented with 10% fetal calf serum (FCS). 2 mM L-glutamine, 10 mM hydroxyethylpiperazineneethanesulfonic acid (HEPES), 1 mM sodium pyruvate, 4.5 g L−1 glucose and 1.5 g L−1 sodium bicarbonate. KATOII cells were grown in Iscove’s Modified Dulbecco Medium (IMDM) growth medium supplemented with 20% FCS and 1.5 g L−1 sodium bicarbonate. UMUC14 cells were grown in Minimum Essential Media (MEM) growth medium supplemented with 10% FCS, non-essential amino acids (NEAA), 2 mM L-glutamine, 1 mM sodium pyruvate, and 1.5 g L−1 sodium bicarbonate. MDA-MB-231 cells were grown in Dulbecco’s Modified Eagle’s Medium-high glucose (DMEM-HG) supplemented with 10% FCS. SKBR3 cells were grown in McCoy’s medium supplemented with 10% FCS, 1.5 mM glutamine, 2.2 g L−1 sodium bicarbonate. MCF-7 cells were grown in Eagle’s Minimum Essential Medium (EMEM) supplemented with 0.01 mg mL−1 of human recombiant insulin and 10% FCS. BT474 cells were grown in a 1:1 mixture of DMEM/F-12 medium, supplemented with 10% FCS, 2 mM glutamine, NEAA. All cell culture media were supplemented with 100 units mL−1 penicillin and streptomycin.

**Organoctypic cultures of fresh human bladder tissues.** Fresh biopsy samples of bladder tissues were obtained immediately after surgical resection by the tissue procurement services at MSKCC. Normal and tumor bladder tissues were kept in organotypic cultures41. Tissue specimens were placed in Ham F-12 media supplemented with 20% inactivated FCS, 100 U mL−1 penicillin, 100 μg mL−1 streptomycin, 2.5 μg mL−1 amphotericin B, and 100 μg mL−1 of kanamycin. A Vibratome (Vibratome VT1200; Leica) was used to cut thin slices (300–500 μm) from biopsy specimens. Samples were soaked in ice-cold phosphate-buffered saline buffer (PBS) and immobilized using cyanoacrylate glue on the Vibratome platform. Tissue slices were cultured on organotypic inserts (Millipore) for up to 96 h at 37 °C in a 5% CO2 humidified incubator. Five tissue slices were harvested at baseline time (T0) and thereafter, at 24 h intervals for viability assays using 1-(4, 5-dimethylthiazol-2-yl)-3, 5-diphenylformazan (MTT, Sigma-Aldrich) and CellTiter-Glo 3D (Promega) assays. For the MTT assay, tissue slices were incubated with 5 mg mL−1 of MTT at 37 °C for 4 h, harvested, and the precipitated-salt extracted by incubation with 0.1 M hydrochloric acid (HCl)-isopropanol alcohol at room temperature for 25 min. A viability value was obtained by dividing the optical density of the formazan at 570 nm by the weight of the explants. Tissue viability was expressed as percentage of viability relative to that of samples at T0. For the CellTiter-Glo 3D cell viability assay, tissues were incubated with 100 μL of the CellTiter-Glo 3D reagent on a plate shaker for 5 min, followed by incubation for 30 min at room temperature. A viability value was obtained by dividing the luminescence signal by the weight of the explants.

**Transfection assays.** CAV1 was depleted using a pool of three target-specific 20–25 nt siRNA (Santa Cruz Biotechnology). Cancer cells were transfected in 6-well culture plates, at 60–80% confluence, with siRNA CAV1. Cells were also transfected with a scrambled siRNA in parallel as controls. For each transfection, cells were treated for 5 h with 2.4 μM of siRNA in transfection medium (Santa Cruz) containing 0.5 μL cm−2 of transfection reagent (Santa Cruz).
Cancer cells were transfected in 6-well culture plates, at 60 mM MgCl₂ and 1 mM calcium chloride (CaCl₂). Cells were incubated with 0.5 mg mL⁻¹ of fisher scienti

For the internalization assays with [⁸⁹Zr]Zr-DFO-trastuzumab, cells were incubated with cell culture medium in the presence of 1 μM [⁸⁹Zr]Zr-DFO-trastuzumab for 90 min at 37 °C. Media containing non-cell-bound radiotracer was removed and the cells were washed twice with PBS. Cell surface-bound radiotracer was collected by cells incubation at 4 °C for 5 min in 0.2 M glycine buffer containing 0.15 M NaCl, 4 M urea at pH 2.5. Internalized fraction was obtained after cell lysis with 1 M sodium hydroxide (NaOH). Finally, the three fractions were measured for radioactivity on a gamma counter calibrated for ⁸⁹Zr.

For the saturation-binding assays, cells were incubated with [⁸⁹Zr]Zr-DFO-trastuzumab (0–128 nM) in PBS (pH 7.5) containing 1% (v/v) human serum albumin (Sigma) and 1% (v/v) bovine serum albumin (Sigma). The cells were solubilized in 100 mM NaOH, recovered, and the total cell-bound radioactivity was measured on a gamma counter calibrated for ⁸⁹Zr. Total binding was plotted vs. the concentration of [⁸⁹Zr]Zr-DFO-trastuzumab; the data were fit via non-linear regression with a one-site binding model in GraphPad Prism 7.00 to determine Bmax, Kd and the non-specific binding component. The non-specific component was subtracted from the total binding to generate specific binding curves (Fig. 2b).

**Uptake in organotypic cultures and autoradiography.** Slices of normal and tumor bladder tissues (n = 4) were harvested after 48 h of ex vivo culture and incubated with 25 μM of the active form of lovastatin for 4 h prior and at the same time as the addition of 1 μM [⁸⁹Zr]Zr-DFO-trastuzumab. Slices were harvested at 3 h after incubation with [⁸⁹Zr]Zr-DFO-trastuzumab, washed with PBS (pH 7.5) containing 0.1% (m/v) bovine serum albumin (BSA), air dried, weighed, and counted in a gamma counter calibrated for ⁸⁹Zr. For autoradiography, slices were mounted in glycergel mounting medium, placed in a film cassette against phosphor imaging plate (Fujiﬁlm BAS-M52325; Fuji Photo Film) for 10 days. Phosphor imaging plates were read at a pixel resolution of 25 μm with a Typhoon 7000 IP plate reader (GE Healthcare).

**In vitro antibody-dependent cellular cytotoxicity (ADCC).** Scr or CAVI-depleted NCIN87, UMC14, BT474, and SK-BR-3 cancer cells (1.7 × 10⁶) were preincubated with trastuzumab (1 μM) for 1.5 h at 37 °C in serum-free cell culture medium supplemented with 0.1% BSA before adding the effector cells in 1:1, 10:1, 25:1, or 50:1 effector to target (T:R) ratios. PBMCs were used as effectors and cancer cells as targets. The cells were incubated for additional 48 h before determination of cell death using the Cytotoxicity Detection Kit (LDH; Roche). The percentage of cytotoxicity was calculated as follows: % cytotoxicity (experimental lysis – spontaneous effector lysis – spontaneous target lysis)/(maximum target lysis – spontaneous target lysis) × 100. Control EC gamma receptor (FcγR) blocking studies were performed by pretreating PBMCs with 10 μg mL⁻¹ of human isotype IgG for 1 h before adding them to cancer cells in a ratio of 50:1.
Additional ADCC experiments were performed with the ADCC Reporter Bioassay, Core Kit (Promega), according to manufacturer instructions. Briefly, Scr or CAV1 depleted NCI/N87, UMUC4, BT474 and SK-BR-3 cancer cells were plated at the density of 5,000 cells/well in complete culture medium overnight before bioassay. On the day of the assay, the medium was removed, and then the series of 10-fold dilutions of trastuzumab ([89Zr]Zr-DFO-trastuzumab) (10–10,000 ng mL⁻¹) were added to the cells, followed by addition of ADCC Bioassay Effector Cells (engineered Jurkat cells that stably express the FcγRIIIa receptor). The E:T ratio was 15:1, according to manufacture instructions. After 6 h of incubation, luciferase assay reagent was added and luminescence determined using a luminometer. The data were fitted to a 4PL curve using GraphPad Prism software.

Tumor xenografts. All animals were treated according to the guidelines approved by the Research Animal Resource Center and Institutional Animal Care and Use Committee at Memorial Sloan Kettering Cancer Center, NY. Pereira PMR has a Category C accreditation for animal research given from Federation of European Laboratory Animal Science (FELASA). We adhere to the animal research: reporting of in vivo experiments (ARRIVE) guidelines and to the guidelines for the welfare and use of animals in cancer research. Eight- to 10-week-old nu/nu female mice (Charles River Laboratories) were injected subcutaneously with 2.5 million UMUC4, 5 million NCI/N87 cells, or 5 million BT474 in a 150 μL cell suspension of a 1:1 (v/v) mixture of medium with reconstituted basement membrane (BD Matrigel, BD Biosciences). Drinking water of mice receiving estrogen receptor-positive cells BT474 was supplemented with 0.67 μg mL⁻¹ 17β-estradiol (Sigma) from 1 week in advance of inoculation until sacrificed. Fresh-estradiol supplemented water was provided twice a week. The mice were housed in type II polycarbonate cages, fed with sterilized standard laboratory diet and received sterile water ad libitum. The animals were housed at approximately 22 °C, 60% relative humidity, and a 12 h light, 12 h dark cycle was maintained. After arrival, all mice were allowed to acclimate to the facility’s laboratory conditions for 1 week prior to experimentation.

Mice-bearing bilateral tumors were developed by subcutaneous injection of cancer cells on the bilateral dorsal flank regions using a sterile syringe with a 28-gauge needle. For experiments with mice-bearing unilateral tumors, cancer cells were subcutaneously injected on the right shoulder. The tumor volume (V mm³) was estimated by external vernier caliper measurements of the longest axis, a, nm, and the axis perpendicular to the longest axis, b, nm. The tumors were assumed to be spheroidal and the volume was calculated in accordance with the equation V = (4π/3) x (a/2)² x (b/2).

An intratumoral injection of the active form of lovastatin (0.44 mg kg⁻¹ of mice) was performed in the pilot study with mice-bearing bilateral tumors. In further experiments with mice-bearing unilateral tumors, lovastatin was orally administered (8.3 mg kg⁻¹ of mice). The doses of lovastatin used in our study were lower when compared with the human maximum dose (80 mg per day): the 0.44 mg kg⁻¹ and 8.3 mg kg⁻¹ of mice doses correspond to daily human doses of 2.15 and 40.14 mg assuming an average human body weight of 60 kg. It should be noted that the intratumoral dose of 0.44 mg kg⁻¹ of lovastatin was defined as 5% of oral dose 8.3 mg kg⁻¹ of mice, assuming 5% lovastatin bioavailability after oral administration.

When the volume of xenografts reached approximately 100 mm³, mice were randomized into groups and treatments initiated. The active form of lovastatin (0.44 mg kg⁻¹ of mice) was intratumorally injected into the left-sided tumor of mice-bearing bilateral tumors (four mice per group) 4 h prior and at the same time as the tail vein injection of [89Zr]Zr-DFO-trastuzumab (8.14–10.18 M bq, 80–100 μg protein). The right-sided tumor was used as the CT and it was intratumorally injected with PBS.

For experiments in mice-bearing unilateral tumors, mice were randomly assigned into the following groups (n = 4 mice per group): Group I, oral administration of PBS 12 h prior to and at the same time as the tail vein injection of [89Zr]Zr-DFO-trastuzumab (8.14–10.18 M bq, 80–100 μg protein); Group II, oral administration of lovastatin (8.3 mg kg⁻¹ of mice) 12 h prior to and at the same time as the tail vein injection of [89Zr]Zr-DFO-IgG (8.14–10.18 M bq, 80–100 μg protein).

Patient-derived xenograft (PDx) mouse models. PDx models were established, by the Anti-tumor Assessment Core, from tumor specimens collected under an approved institutional review board protocol by the Research Animal Resource Center and Institutional Animal Care and Use Committee at Memorial Sloan Kettering Cancer Center, NY. Briefly, tumors were minced, mixed with Matrigel, and implanted subcutaneously in 6 to 8-week-old female NCR-nu/nu (Jackson Laboratories). Once established, tumors were maintained and expanded by serial subcutaneous transplantation. Tumor samples were evaluated by immunohistochemistry and graded for HER2 and CAV1 expression.

Acute biodistribution studies. Acute biodistribution studies were performed after injection of radiolabeled trastuzumab. Mice were sacrificed and organs were harvested, weighed, and assayed in the gamma counter for biodistribution studies.

Radioactivity associated with each organ was expressed as percentage of injected dose per gram of organ (% ID g⁻¹).

Small-Animal positron emission tomography (PET) Imaging. PET imaging experiments were conducted on a microPET Focus 120 scanner (Concorde Microsystems). Mice were anesthetized by inhalation of 1.5–2% isoflurane (Baxter Healthcare) in an oxygen gas mixture 10 min before recording PET images. PET data for each group (n = 4) was recorded, with mice under isoflurane anesthesia (1.5–2%), in list mode at 4, 8, 24, and 48 h after intravenous injection of [89Zr]Zr-DFO-trastuzumab or [89Zr]Zr-DFO-IgG. Images were analyzed using ASIPro VM software (Concorde Microsystems).

In vivo therapeutic efficacy. When tumor volumes reached 100 to 300 mm³, mice were randomly grouped into treatment cohorts (n ≥ 8 per group): vehicle, trastuzumab, lovastatin, or a combination of trastuzumab with lovastatin. Intraipertinal administration of 5 mg kg⁻¹ weekly (during 5 weeks) was started at day 0. Lovastatin (4.15 mg kg⁻¹ of mice) was orally administered 12 h prior and at the same time as the intraperitoneal injection of trastuzumab. Tumor volumes were determined twice a week.

Statistical analysis. Data are expressed as mean ± S.E.M. Differences were analyzed by the Student t-test. The non-parametric one-tailed Spearman test was used to determine the correlation coefficient.

Data availability. All data supporting the findings of this study are available in the Article, Supplementary Information, or upon request from the corresponding author. The Source Data underlying Figures in the main text and Supplementary Figures are provided as a Source Data file.

Received: 12 April 2018 Accepted: 13 November 2018 Published online: 03 December 2018

References
1. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).
2. Yan, M. et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metast. Rev. 34, 157–164 (2015).
3. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
4. Baselga, J. & Swain, S. M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9, 463–479 (2009).
5. Pereira, P. M., Abnna, L., Henry, K. E. & Lewis, J. Imaging of human epidermal growth factor receptors for patient selection and response monitoring: From PET imaging and beyond. Cancer Lett. 419, 139–151 (2018).
6. O’Donoghue, J. A. et al. Pharmacokinetics, biodistribution, and radiation dosimetry for [89Zr]-trastuzumab in patients with esophagogastric cancer. J. Nucl. Med. 59, 161–166 (2018).
7. Ulaner, G. A. et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using [89Zr]-Trastuzumab PET/CT. J. Nucl. Med. 57, 1523–1528 (2016).
8. Janjigian, Y. Y. et al. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-Trastuzumab PET. J. Nucl. Med. 54, 936–943 (2013).
9. Janjigian, Y. Y. et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 8, 49–58 (2018).
10. Jordan, N. V. et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature 537, 102–106 (2016).
11. Turner, N. H. & Di Leo, A. HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact. Cancer Treat. Rev. 39, 947–957 (2013).
12. Lindström, L. S. et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J. Clin. Oncol. 30, 2601–2608 (2012).
13. Niikura, N. et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J. Clin. Oncol. 30, 593–599 (2012).
14. Gehbhart, G. et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1)-the ZEPHIR trial. Ann. Oncol. 27, 619–624 (2016).
15. Moasser, M. M. Targeting the function of the HER2 oncogene in human cancer therapeutics. 
Oncogene 26, 6577–6592 (2007).

16. Liu, D. et al. 2-AR signaling controls trastuzumab resistance-dependent pathway. 
Oncogene 35, 47–58 (2016).

17. Gennari, R. et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. 
Clin. Cancer Res. 10, 3650–3655 (2004).

18. Zolfi, A. C. & Gol, L. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/ 
College of american pathologists clinical practice guideline update. J. Clin. Oncol. 
31, 3997–4013 (2013).

19. Mosesson, Y., Mills, G. B. & Yarden, Y. Derailed endocytosis: an emerging biological role of homo- and heteroassociations of ErbB2. 
Oncogene 33, 3422–3431 (2014).

20. Sorkin, A. & Goh, L. K. Endocytosis and intracellular trafficking of ErbBs. 
Exp. Cell Res. 315, 683–696 (2009).

21. Garrett, T. P. et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErBb receptors. 
Mol. Cell 11, 495–505 (2003).

22. Cho, H. S. et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. 
Nature 421, 756–760 (2003).

23. Austin, C. D. et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. 
Mol. Biol. Cell 15, 5268–5282 (2004).

24. Bertelsen, V. & Stang, E. The mysterious ways of ErbB2/HER2 trafficking. 
Membranes (Basel) 4, 424–446 (2014).

25. Roepstorff, K., Grawd, L., Grandal, M., Lerdrup, M. & van Deurs, B. 
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. 
Histochim. Cell Biol. 129, 563–578 (2008).

26. Half, E. et al. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. 
Int. J. Cancer 108, 540–548 (2003).

27. Wang, Y. -N., Yamaguchi, H., Hsu, J. -M. & Hung, M. -C. Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. 
Oncogene 29, 3997–4006 (2010).

28. Nagy, P. et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. 
J. Cell Sci. 115, 4251–4262 (2002).

29. Shatz, M. & Liscovitch, M. Caveolin-1: A tumor-promoting role in human cancer. 
Oncogene 28, 835–838 (2009).

30. Verquin, A. & Gol, L. K. Endocytosis and intracellular trafficking of ErbBs. 
Exp. Cell Res. 315, 683–696 (2009).

31. Garrett, T. P. et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErBb receptors. 
Mol. Cell 11, 495–505 (2003).

32. Cho, H. S. et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. 
Nature 421, 756–760 (2003).

33. Austin, C. D. et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. 
Mol. Biol. Cell 15, 5268–5282 (2004).

34. Bertelsen, V. & Stang, E. The mysterious ways of ErbB2/HER2 trafficking. 
Membranes (Basel) 4, 424–446 (2014).

35. Roepstorff, K., Grawd, L., Grandal, M., Lerdrup, M. & van Deurs, B. 
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. 
Histochim. Cell Biol. 129, 563–578 (2008).

36. Half, E. et al. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. 
Int. J. Cancer 108, 540–548 (2003).

37. Wang, Y. -N., Yamaguchi, H., Hsu, J. -M. & Hung, M. -C. Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. 
Oncogene 29, 3997–4006 (2010).

38. Nagy, P. et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. 
J. Cell Sci. 115, 4251–4262 (2002).

39. Shatz, M. & Liscovitch, M. Caveolin-1: A tumor-promoting role in human cancer. 
Oncogene 28, 835–838 (2009).

40. Verquin, A. & Gol, L. K. Endocytosis and intracellular trafficking of ErbBs. 
Exp. Cell Res. 315, 683–696 (2009).

41. Vaira, V. et al. Preclinical model of organotypic culture for pharmacodynamic 
analysis of the data. L.M.C. acknowledges support from the Ruth L. Kirschstein National 
Research Service Award postdoctoral fellowship (NIH F32 EB025050). P.M.R.P. and
S.K.S. gratefully acknowledge the Tow Foundation Postdoctoral Fellowships from the MSKCC Center for Molecular Imaging and Nanotechnology.

**Author contributions**
Conception and design: P.M.R.P., J.S.L. Development of methodology: P.M.R.P., L.C., K.J.E., J.P., A.R. Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P.M.R.P., L.C., J.C.D., Y.Y.J., J.S.L. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P.M.R.P., L.C., S.K.S., J.S.L. Writing, review, and/or revision of the manuscript: P.M.R.P., L.C., K.J.E., S.K.S., J.C.D., Y.Y.J., J.S.L. Study supervision: J.S.L.

**Additional information**
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-018-07608-w.

**Competing interests:** The authors declare no competing interests.

**Reprints and permission** information is available online at http://npg.nature.com/reprintsandpermissions/

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.